Table of Content

1 Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2 Research Methodology
2.1. Research Approach
2.2. Process Of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders Of The Industry
2.3. Market Sizing & forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth forecast Approach
2.4. Assumptions for the Study

3 Executive Summary

4 Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Drivers
4.2.1.1. Rising Prevalence of Chronic and Infectious Diseases
4.2.1.2. Technological Advancements in Molecular Diagnostics
4.2.1.3. Increasing Healthcare Expenditure
4.2.2. Restraints
4.2.2.1. Lack of Harmonization of Regulations Across Southeast Asian Countries
4.2.2.2. High Costs of Molecular Diagnostics Tests
4.2.3. Opportunities
4.2.3.1. Increasing Focus on Companion Diagnostics
4.2.3.2. Emerging Medical Tourism in Southeast Asian Countries
4.2.4. Challenges
4.2.4.1. Shortage of Skilled Professionals
4.2.5. Industry & Technology Trends
4.2.5.1. Integration of Artificial Intelligence and Machine Learning
4.2.5.2. Development of Rapid and Point of Care Molecular Testing
4.2.5.3. High Throughput, Multiplexing, and Automation
4.3. Regulatory Analysis
4.4. Pricing Analysis

5 Southeast Asia Molecular Diagnostics Market Assessment-by Offering
5.1. Overview
5.2. Kits & Reagents
5.3. Instruments
5.4. Software & Services

6 Southeast Asia Molecular Diagnostics Market Assessment-by Test Type
6.1. Overview
6.2. Laboratory Tests
6.3. Point-Of-Care (POC) Tests

7 Southeast Asia Molecular Diagnostics Market Assessment-by Technology
7.1. Overview
7.2. Polymerase Chain Reaction (PCR)
7.3. In Situ Hybridization (ISH)
7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
7.5. Microarrays
7.6. Sequencing
7.7. Mass Spectrometry
7.8. Other Technologies

8 Southeast Asia Molecular Diagnostics Market, by Application
8.1. Introduction
8.2. Infectious Diseases
8.2.1. Respiratory Diseases
8.2.2. Hepatitis
8.2.3. HIV
8.2.4. Healthcare-Associated Infections (HAI)
8.2.5. Chlamydia Trachomatis/Neisseria Gonorrhoeae (CT/NG)
8.2.6. Human Papillomavirus (HPV)
8.2.7. Other Infectious Diseases
8.3. Oncology
8.3.1. Breast Cancer
8.3.2. Lung Cancer
8.3.3. Colorectal Cancer
8.3.4. Prostate Cancer
8.3.5. Lymphoma
8.3.6. Leukemia
8.3.7. Cervical Cancer
8.3.8. Other Cancer Types
8.4. Genetic Testing
8.5. Neurological Diseases
8.6. Cardiovascular Diseases
8.7. Other Applications

9 Southeast Asia Molecular Diagnostics Market Assessment–by End User
9.1. Overview
9.2. Hospitals & Clinics
9.3. Diagnostic Laboratories
9.4. Academic & Research Institutes
9.5. Other End Users

10 Southeast Asia Molecular Diagnostics Market Assessment?by Country
10.1. Overview
10.2. Indonesia
10.3. Vietnam
10.4. Thailand
10.5. Singapore
10.6. Philippines
10.7. Malaysia
10.8. Rest Of Southeast Asia

11 Competitive Landscape
11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share Analysis (2023)
11.5.1. F. Hoffmann-La Roche Ltd (Switzerland)
11.5.2. Abbott Laboratories (U.S.)
11.5.3. Hologic Inc. (U.S.)

12 Company Profiles
12.1. Illumina, Inc.
12.2. Thermo Fisher Scientific Inc.
12.3. F. Hoffmann-La Roche Ltd
12.4. Hologic, Inc.
12.5. Sansure Biotech Inc.
12.6. Agilent Technologies, Inc.
12.7. Danaher Corporation
12.8. Abbott Laboratories
12.9. Qiagen N.V.
12.10. Xiamen Zeesan Biotech Co., Ltd.



List of Figures

Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand Side)
Figure 6 Market Sizing and Growth forecast Approach
Figure 7 Southeast Asia Molecular Diagnostics Market, by Offering, 2024 Vs. 2031 (USD Million)
Figure 8 Southeast Asia Molecular Diagnostics Market, by Test Type, 2024 VS. 2031 (USD Million)
Figure 9 Southeast Asia Molecular Diagnostics Market, by Technology, 2024 VS. 2031 (USD Million)
Figure 10 Southeast Asia Molecular Diagnostics Market, by Application, 2024 VS. 2031 (USD Million)
Figure 11 Southeast Asia Molecular Diagnostics Market, by End User, 2024 VS. 2031 (USD Million)
Figure 12 Southeast Asia Molecular Diagnostics Market, by Geography, 2024 VS. 2031 (USD Million)
Figure 13 Impact Analysis of Market Dynamics
Figure 14 Southeast Asia Molecular Diagnostics Market, by Offering, 2024 VS. 2031 (USD Million)
Figure 15 Southeast Asia Molecular Diagnostics Market, by Test Type, 2024 VS. 2031 (USD Million)
Figure 16 Southeast Asia Molecular Diagnostics Market, by Technology, 2024 VS. 2031 (USD Million)
Figure 17 Southeast Asia Molecular Diagnostics Market SIZE, by Application, 2024 VS. 2031 (USD Million)
Figure 18 NEW CANCER CASES In Southeast Asia, by Cancer Type, 2022
Figure 19 Southeast Asia Molecular Diagnostics Market, by End User, 2024 VS. 2031 (USD Million)
Figure 20 Southeast Asia Molecular Diagnostics Market, by Country/Region, 2024 Vs. 2031 (USD Million)
Figure 21 Southeast Asia: Molecular Diagnostics Market Snapshot
Figure 22 Key Growth Strategies Adopted by Leading Players, 2021-2024
Figure 23 Southeast Asia Molecular Diagnostics Market: Competitive Benchmarking (Based on Technology)
Figure 24 Southeast Asia Molecular Diagnostics Market: Competitive Benchmarking (Based on Offering)
Figure 25 Competitive Dashborad: Southeast Asia Molecular Diagnostics Market
Figure 26 Southeast Asia Molecular Diagnostics Market Share Analysis by Key Players (2023)
Figure 27 Illumina, Inc.: Financial Snapshot (2023)
Figure 28 Thermo Fisher Scientific Inc.: Financial Snapshot (2023)
Figure 29 F. Hoffmann-La Roche Ltd.: Financial Snapshot (2023)
Figure 30 Hologic, Inc.: Financial Snapshot (2023)
Figure 31 Sansure Biotech Inc.: Financial Snapshot (2023)
Figure 32 Agilent Technologies, Inc.: Financial Snapshot (2023)
Figure 33 Danaher Corporation: Financial Snapshot (2023)
Figure 34 Abbott Laboratories: Financial OVERVIEW (2023)
Figure 35 Qiagen N.V.: Financial Snapshot (2023)